Press Releases

Press Releases

May 29, 2020
Iovance Presents Updated Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel in Advanced Melanoma at ASCO Scientific Program
Median Duration of Response Not Reached at 18.7 Months of Median Study Follow Up 36.4% Overall Response Rate (ORR) Maintained SAN CARLOS, Calif. , May 29, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer
May 28, 2020
Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of Approximately $525 Million of Common Stock
SAN CARLOS, Calif. , May 28, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics , Inc. (Nasdaq:IOVA) (“Iovance” or “Company”), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today
May 27, 2020
Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock
SAN CARLOS, Calif. , May 27, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics , Inc. (Nasdaq: IOVA) (“Iovance” or “Company”), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL and peripheral-blood lymphocyte, PBL), today
May 27, 2020
Iovance Reports Pivotal Cohort 4 Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel from C-144-01 Clinical Study in Advanced Melanoma
Cohort 4 Early Data Shows 32.4% ORR by Investigator Assessment at 5.3 Months of Median Study Follow up Cohort 2 Median Duration of Response Not Reached at 18.7 Months of Median Study Follow Up and 36.4% ORR SAN CARLOS, Calif. , May 27, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc.
May 13, 2020
Iovance Biotherapeutics Announces Clinical Data Updates for Lifileucel in Advanced Melanoma
Median Duration of Response Not Reached at 17.0 Months  of Median Study Follow Up in C-144-01 Study Oral Presentation to Include Additional Cohort 2 Data from C-144-01 Clinical Study at ASCO 2020 Virtual Scientific Program SAN CARLOS, Calif. , May 13, 2020 (GLOBE NEWSWIRE) -- Iovance
May 05, 2020
Iovance Biotherapeutics Reports First Quarter 2020 Financial Results and Provides a Corporate Update
SAN CARLOS, Calif. , May 05, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL and peripheral-blood lymphocyte, PBL), today reported first quarter 2020
April 29, 2020
Iovance Biotherapeutics to Present Updated Data from Clinical Study in Advanced Melanoma at ASCO 2020 Virtual Scientific Program
Oral Presentation of Updated Cohort 2 Data from C-144-01 Clinical Study will be Provided SAN CARLOS, Calif. , April 29, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced
April 27, 2020
Iovance Biotherapeutics to Host First Quarter 2020 Financial Results Conference Call and Webcast on Tuesday, May 5, 2020
SAN CARLOS, Calif. , April 27, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its first quarter 2020 financial results on Tuesday, May 5, 2020 .
April 13, 2020
Iovance Biotherapeutics Announces H. Lee Moffitt Cancer Center to Present Lung Cancer Clinical Data at American Association for Cancer Research (AACR) Virtual Annual Meeting 2020
Phase 1 Study Combining Tumor Infiltrating Lymphocytes (TIL) and Nivolumab in Non-Small Cell Lung Cancer Funded in Part by Iovance and Stand Up To Cancer SAN CARLOS, Calif. , April 13, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company
March 02, 2020
Iovance Biotherapeutics to Present at Upcoming Conferences
SAN CARLOS, Calif. , March 02, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the company plans to present at the following conferences: Cowen 40th Annual Health
February 25, 2020
Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update
SAN CARLOS, Calif. , Feb. 25, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL and peripheral-blood lymphocyte, PBL), today reported fourth quarter and
February 19, 2020
Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call and Webcast on Tuesday, February 25, 2020
SAN CARLOS, Calif. , Feb. 19, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its fourth quarter and full year 2019 financial results on Tuesday, February 25, 2020 .
February 12, 2020
Iovance Biotherapeutics to Present at Upcoming Healthcare Conferences
SAN CARLOS, Calif. , Feb. 12, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the company plans to present at the following conferences: Guggenheim Healthcare Talks |
January 15, 2020
Iovance Biotherapeutics Completes Patient Dosing in Registration-Enabling Cohort 4 of the C-144-01 Melanoma Study with Lifileucel
- Biologics Licensing Application (BLA) submission planned for late 2020 - SAN CARLOS, Calif. , Jan. 15, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the company
January 12, 2020
Iovance Biotherapeutics Obtains License to Develop and Commercialize a Novel IL-2 Analog
SAN CARLOS, Calif. , Jan. 12, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the company has obtained a license from Novartis to develop and commercialize an
January 12, 2020
Iovance Biotherapeutics and Cellectis Enter into a Research Collaboration and Exclusive Worldwide License Agreement
Iovance Biotherapeutics Will Use TALEN® Technology from Cellectis to Develop Gene-Edited TIL SAN CARLOS, Calif. and NEW YORK , Jan. 12, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, and